FMP
Lysogene S.A.
LYS.PA
EURONEXT
Inactive Equity
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.
0.28 EUR
0 (0%)
About
ceo
Ms. Karen Pignet-Aiach MBA
sector
Healthcare
industry
Biotechnology
website
https://www.lysogene.com
exchange
EURONEXT
Description
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.
CIK
N/A
ISIN
FR0013233475
CUSIP
F58864103
Address
18-20 rue Jacques Dulud
Phone
33 1 41 43 03 90
Country
FR
Employee
22
IPO Date
Feb 8, 2017
Summary
CIK
-
Exchange
EURONEXT
Industry
Biotechnology
Sector
Healthcare
CUSIP
F58864103
ISIN
FR0013233475
Country
FR
Price
0.28
Beta
0.91
Volume Avg.
0
Market Cap
4.95M
Shares
-
52-Week
0.225-0.819
DCF
0
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.64
P/B
-
Website
https://www.lysogene.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LYS.PA News
It looks like there's no news available.
